Drugs / Vitamin E δ-Tocotrienol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01450046 | Oct 2011 → Mar 2013 | malignant pancreatic neoplasm | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT00985777 | Sep 2009 → Jun 2015 | pancreatic neoplasm | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vitamin E δ-Tocotrienol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01450046 ↗ |
| Known as | VEDT | “Vitamin E δ-tocotrienol (VEDT), a natural vitamin E from plants, has shown anti-neoplastic and chemoprevention activity in preclinical models of pancreatic cancer.” PMID 26844278 ↗ Nov 2015 |
| Route | Oral | “Patients received oral VEDT at escalating doses (from 200 to 3200 mg) daily for 13 days before surgery and one dose on the day of surgery.” PMID 26844278 ↗ Nov 2015 |